Grandem Syrup contains Granisetron at a concentration of 1mg per 5ml and is indicated for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative conditions. Granisetron is a selective 5-HT3 receptor antagonist that works by blocking serotonin receptors located on vagal nerve terminals and in the central nervous system, thereby inhibiting the emetic signals responsible for triggering nausea and vomiting. This syrup formulation allows for ease of administration, particularly in pediatric and geriatric patients or those who have difficulty swallowing tablets. The onset of action is rapid, typically within one hour, providing effective symptomatic relief. Grandem Syrup should be administered as directed by a healthcare professional, with dosage adjusted according to the patient’s age, weight, and clinical condition. Common adverse effects may include headache, constipation, and dizziness, though the medication is generally well tolerated. Caution is advised in patients with hepatic impairment, and it is contraindicated in individuals with known hypersensitivity to Granisetron or any of the syrup’s excipients. As with all antiemetics, it is essential to monitor for potential drug interactions and use under medical supervision to ensure safety and efficacy.